Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | Director | September 28, 2026 | September 30, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | December 28, 2022 | December 30, 2022 |
| OmniAb, Inc.OABI · Entity 5294 | Director | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,254 |
Ending reported balance
After 2026-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-28 · Exercise / conversion · Acquired 15,940 · Balance 82,816 Row 2 · 2026-09-28 · Tax withholding · Disposed 5,562 · Balance 77,254 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2026-10-26 | Direct | 0 |
Reported balance
After 2026-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-28 · Exercise / conversion · Disposed 15,940 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.26 · Expires 2027-10-26 | Direct | 12,500 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 12,500 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.96 · Expires 2028-10-25 | Direct | 7,592 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,592 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.41 · Expires 2029-10-24 | Direct | 8,044 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,044 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.92 · Expires 2030-10-29 | Direct | 6,028 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 6,028 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $128.81 · Expires 2031-10-28 | Direct | 2,532 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 2,532 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.94 · Expires 2032-10-27 | Direct | 3,460 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 3,460 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.51 · Expires 2033-10-26 | Direct | 3,937 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 3,937 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.37 · Expires 2034-10-24 | Direct | 3,511 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 3,511 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.96 · Expires 2035-10-30 | Direct | 3,777 |
Reported balance
Holding disclosure · report date 2026-09-28 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 3,777 F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
LIGAND PHARMACEUTICALS INC
Report date December 28, 2022 · Filed December 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 417,695 |
Reported balance
After 2022-12-28 transaction · row 1
1 source rowRow 1 · 2022-12-28 · Tax withholding · Disposed 5,289 · Balance 417,695 |
OmniAb, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,962,320 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Exercise / conversion · Acquired 20,000 · Balance 2,962,320 F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Exercise / conversion · Disposed 20,000 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2026-06-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-17 · Grant · Acquired 20,000 · Balance 20,000 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.03 · Expires 2036-06-17 | Direct | 40,000 |
Reported balance
After 2026-06-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-17 · Grant · Acquired 40,000 · Balance 40,000 F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU granted on June 17, 2025, which occurs on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the grant date.
F4: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 09, 2020 Filed Nov 11, 2020 00:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0000886163-20-000124 · edgardoc.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,657 Underlying: Common Stock · 20,000 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/17/11. Read SEC document |
| November 09, 2020 Filed Nov 11, 2020 00:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,458 | $81.77 | $200,990.66 |
DisclosureSEC source: 0000886163-20-000124 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,113 F1 · shares: Represents previously-owned shares delivered to the Issuer in payment of the exercise price of the stock options. Read SEC document |
| November 09, 2020 Filed Nov 11, 2020 00:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 20,000 | $10.05 | $201,000.00 |
DisclosureSEC source: 0000886163-20-000124 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · derivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 3,100 | $301.06 | $933,300.57 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,412 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $300.9950 to $301.0647, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 450 | $299.84 | $134,927.64 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,512 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $299.6050 to $300.4491, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 1,450 | $298.98 | $433,515.93 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,962 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $298.5100 to $299.2800, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 06, 2020 Filed Nov 10, 2020 21:53 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $70.35 | $351,750.00 |
DisclosureSEC source: 0001562180-20-006646 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $255.69 | $0.00 |
DisclosureSEC source: 0001562180-20-006489 · primarydocument.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 1,507 shares Expires 2030-10-29 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/29/2020) or the date of Bio-Techne's 2021 annual meeting of shareholders. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 20:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 391 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006489 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,412 Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,165 | $0.00 Strike: $85.79 | $0.00 |
DisclosureSEC source: 0000886163-20-000087 · edgardoc.xml · derivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,226 Underlying: Common Stock · 1,165 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/11/16. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,373 | $0.00 Strike: $74.42 | $0.00 |
DisclosureSEC source: 0000886163-20-000087 · edgardoc.xml · derivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,627 Underlying: Common Stock · 1,373 shares Expires 2024-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/12/14. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,777 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0000886163-20-000087 · edgardoc.xml · derivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,421 Underlying: Common Stock · 1,777 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/10/15. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,373 | $74.42 | $102,178.66 |
DisclosureSEC source: 0000886163-20-000087 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,777 | $56.26 | $99,974.02 |
DisclosureSEC source: 0000886163-20-000087 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 20:28 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 1,165 | $85.79 | $99,945.35 |
DisclosureSEC source: 0000886163-20-000087 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,117 | $97.23 | $205,835.91 |
DisclosureSEC source: 0000886163-20-000017 · edgardoc.xml · nonDerivative · entry 6 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,173 F4 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,310 | $97.23 | $127,371.30 |
DisclosureSEC source: 0000886163-20-000017 · edgardoc.xml · nonDerivative · entry 5 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,290 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,689 | $97.23 | $164,221.47 |
DisclosureSEC source: 0000886163-20-000017 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,600 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 48,125 | $0.00 Strike: $9.96 | $0.00 |
DisclosureSEC source: 0000886163-20-000017 · edgardoc.xml · derivative · entry 8 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,125 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/10. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 60,886 | $0.00 Strike: $95.68 | $0.00 |
DisclosureSEC source: 0000886163-20-000017 · edgardoc.xml · derivative · entry 7 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,886 Underlying: Common Stock · 60,886 shares Expires 2030-02-13 F5 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/13/2020. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 13,559 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-20-000017 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,289 Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 5,009 | $95.68 | $479,261.12 |
DisclosureSEC source: 0000886163-20-000017 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,730 F1 · shares: Represents previously-owned shares delivered to the Issuer in payment of the exercise price of the stock options. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Exercise / conversionCommon Stock | 48,125 | $9.96 | $479,325.00 |
DisclosureSEC source: 0000886163-20-000017 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $61.46 | $0.00 |
DisclosureSEC source: 0000914190-20-000070 · edgar.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2020-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $205.23 | $1,026,132.50 |
DisclosureSEC source: 0000914190-20-000070 · edgar.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,021 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.00 to $205.62, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $61.46 | $307,300.00 |
DisclosureSEC source: 0000914190-20-000070 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 2,948 | $105.87 | $312,104.76 |
DisclosureSEC source: 0000886163-19-000206 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,614 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 5,946 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000206 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,562 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2019. On December 20, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,801 | $105.87 | $402,411.87 |
DisclosureSEC source: 0000886163-19-000206 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,616 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 19:00 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 7,668 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000206 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,417 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/29/2017 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2019. On December 20, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 2,011 | $0.00 Strike: $201.64 | $0.00 |
DisclosureSEC source: 0001624404-19-000010 · edgar.xml · derivative · entry 12 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011 Underlying: Common Stock · 2,011 shares Expires 2029-10-24 F1 · derivative.exercise_date: The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders. Read SEC document |
| October 24, 2019 Filed Oct 28, 2019 20:59 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 495 | $0.00 | $0.00 |
DisclosureSEC source: 0001624404-19-000010 · edgar.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,021 Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 14:14 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Purchase0.75% Convertible Senior Notes due 2023 · Derivative | Not disclosed | $841,250.00 Strike: $248.48 | $1,000,000.00 |
DisclosureSEC source: 0000886163-19-000174 · edgardoc.xml · derivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2023-05-15 F1 · derivative.exercise_date: The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. Read SEC document |
| September 19, 2019 Filed Sep 24, 2019 23:11 UTC Amendment | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Purchase0.75% Convertible Senior Notes due 2023 · Derivative | Not disclosed | $988,468.75 Strike: $248.48 | $1,175,000.00 |
DisclosureSEC source: 0000886163-19-000177 · edgardoc.xml · derivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2023-05-15 F1 · security: This amendment is being filed to correct the amount of securities purchased. The original Form 4 reported that the principal amount of 0.75% Convertible Senior Notes due 2023 was $1,000,000 with a purchase price of $841,250. The reporting person actually purchased $1,175,000 principal amount for a purchase price of $988,468.75 on the transaction date. F2 · derivative.exercise_date: The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. Read SEC document |
| July 31, 2019 Filed Jul 31, 2019 23:26 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 1,850 | $95.45 | $176,582.50 |
DisclosureSEC source: 0000886163-19-000134 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,749 Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to buy) · Derivative | 5,000 | $0.00 Strike: $63.03 | $0.00 |
DisclosureSEC source: 0001562180-19-003396 · primarydocument.xml · derivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2019-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | SaleCommon Stock | 5,000 | $203.67 | $1,018,345.50 |
DisclosureSEC source: 0001562180-19-003396 · primarydocument.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,526 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.21 to $204.06 , inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 20:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 5,000 | $63.03 | $315,150.00 |
DisclosureSEC source: 0001562180-19-003396 · primarydocument.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2019 Filed May 31, 2019 23:29 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 1,000 | $108.20 | $108,202.00 |
DisclosureSEC source: 0000886163-19-000093 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,899 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $108.20 to $108.22, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2019 Filed May 14, 2019 23:57 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 2,500 | $113.50 | $283,750.00 |
DisclosureSEC source: 0000886163-19-000081 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,899 Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 17:58 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | PurchaseCommon Stock | 2,500 | $114.29 | $285,725.00 |
DisclosureSEC source: 0000886163-19-000053 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,399 Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,310 | $120.86 | $158,326.60 |
DisclosureSEC source: 0000886163-20-000050 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,982 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 03/02/2018. Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,689 | $120.86 | $204,132.54 |
DisclosureSEC source: 0000886163-20-000050 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,292 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 15, 2019 Filed Apr 24, 2020 23:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,918 | $120.86 | $231,809.48 |
DisclosureSEC source: 0000886163-20-000050 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,981 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 58,596 | $0.00 Strike: $117.97 | $0.00 |
DisclosureSEC source: 0000886163-19-000035 · edgardoc.xml · derivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,596 Underlying: Common Stock · 58,596 shares Expires 2029-03-02 F1 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/19. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 12,809 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000035 · edgardoc.xml · nonDerivative · entry 1 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,899 Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,168 | $111.78 | $354,119.04 |
DisclosureSEC source: 0000886163-19-000017 · edgardoc.xml · nonDerivative · entry 4 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,090 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 6,390 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-19-000017 · edgardoc.xml · nonDerivative · entry 3 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,258 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 03/29/2017 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2018. On January 23, 2019, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:31 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 3,597 | $111.78 | $402,072.66 |
DisclosureSEC source: 0000886163-19-000017 · edgardoc.xml · nonDerivative · entry 2 HIGGINS JOHN L · CIK 0001208906 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,868 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.